We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
F icon
151
CALL
Ford
F
$62.5B
– –
-3,500,000
Closed -$52M
GM icon
152
CALL
General Motors
GM
$81.8B
– –
-2,000,000
Closed -$118M
LFST icon
153
Lifestance Health
LFST
$4.25B
– –
-500,000
Closed -$13.9M
LU icon
154
Lufax Holding
LU
$1.33B
– –
-12,500
Closed -$565K
MCRB icon
155
Seres Therapeutics
MCRB
$45.1M
– –
-10,000
Closed -$4.77M
MOLN
156
Molecular Partners
MOLN
$144M
– –
-100,000
Closed -$2.05M
PARA
157
DELISTED
Paramount Global Class B
PARA
– –
-75,000
Closed -$3.39M
NEUE
158
DELISTED
NeueHealth
NEUE
– –
-3,819
Closed -$5.24M
TRIL
159
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-2,500,000
Closed -$24.3M
TBIO
160
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-500,000
Closed -$13.8M
CEREW
161
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-79,600
Closed -$1.15M
CHMA
162
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-380,000
Closed -$1.8M
BHVN
163
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-400,000
Closed -$38.8M
3 4 5 6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.